SEC Filings

Filing links are provided when reliable SEC filing data is available.

Recent Filings

Form	Filing Date	Accepted	Document
4	Sep 22, 2026	Sep 22, 2026	View filing
4	Sep 22, 2026	Sep 22, 2026	View filing
8-K	Aug 20, 2026	Aug 20, 2026	View filing
10-Q	Aug 14, 2026	Aug 14, 2026	View filing
424B3	Jul 6, 2026	Jul 6, 2026	View filing
8-K	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
EFFECT	Jun 10, 2026	Jun 11, 2026	View filing
S-1	May 29, 2026	May 29, 2026	View filing
10-Q	May 14, 2026	May 14, 2026	View filing
DEFA14A	May 1, 2026	May 1, 2026	View filing
DEF 14A	Apr 30, 2026	Apr 30, 2026	View filing
8-K	Apr 22, 2026	Apr 22, 2026	View filing
8-K	Apr 21, 2026	Apr 21, 2026	View filing
8-K	Apr 13, 2026	Apr 13, 2026	View filing
424B5	Apr 1, 2026	Apr 1, 2026	View filing
8-K	Apr 1, 2026	Apr 1, 2026	View filing
8-K	Mar 30, 2026	Mar 30, 2026	View filing
10-K	Mar 19, 2026	Mar 19, 2026	View filing
8-K	Feb 23, 2026	Feb 20, 2026	View filing
8-K	Feb 17, 2026	Feb 17, 2026	View filing
8-K	Dec 30, 2025	Dec 30, 2025	View filing
424B3	Dec 1, 2025	Dec 1, 2025	View filing
EFFECT	Nov 25, 2025	Nov 26, 2025	View filing
10-Q	Nov 14, 2025	Nov 14, 2025	View filing
424B5	Nov 7, 2025	Nov 7, 2025	View filing
8-K	Oct 24, 2025	Oct 24, 2025	View filing
S-1	Oct 10, 2025	Oct 10, 2025	View filing

About Bullfrog AI Holdings, Inc. Common Stock

BullFrog AI Holdings, Inc., along with its affiliated entities, functions as an advanced digital biopharmaceutical firm. Its core mission involves harnessing artificial intelligence and machine learning (AI/ML) to process and interpret extensive medical and healthcare datasets specifically within the United States. A central offering is bfLEAP, a proprietary AI/ML platform meticulously crafted for the thorough examination of both preclinical and clinical research data. The company has also secured critical intellectual property through licensing agreements. One such accord, with George Washington University, provides rights to utilize siRNA targeting Beta2-spectrin. This technology is being investigated for its therapeutic potential across a spectrum of human conditions, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH). Additionally, a partnership with Johns Hopkins University grants access to a distinct Mebendazole formulation, developed for the treatment of various human cancers or neoplastic diseases. Founded in 2017, BullFrog AI Holdings, Inc. operates from its headquarters in Gaithersburg, Maryland.

Gaithersburg, MD

9 employees

www.bullfrogai.com

Healthcare / Medical - Healthcare Information Services

Sector: Healthcare
Industry: Medical - Healthcare Information Services
CEO: Vininder Singh

View full financials